Structure Encountered
Aspera Biomedicines
Develops ADAR1-targeting small molecules to overcome cancer therapy resistance and immune evasion
Aspera's 11th ISS mission and second ADAR1p150 microgravity crystallization launched on SpaceX CRS-34 to support an oral Rebecsinib. NASA In Space Production Apps Phase 2 funded.
SIGNAL·Research/preclinical milestone (microgravity protein crystallization launch)·Second ADAR1p150 protein crystallization experiment launched to ISS aboard SpaceX CRS-34 (docked May 17, 2026). Aspera's 11th ISS mission overall and second ADAR1p150 flight (first was Crew-12, February 2026). Funded under NASA In Space Production Applications Phase 2.·SCORE 76·19 MAY 2026 · 12:47 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / ASPERA BIOMEDICINES
/ San Diego, CA, USA
CAPT. / 19.05.26 12:47:05Z
SIGNAL / 76 / 100
Image relayed by The Biotech Voyager during pass over structure Aspera Biomedicines. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Aspera Biomedicines
Coordinates
San Diego, CA, USA
Stage
Phase 1
Type
Therapeutics
Modalities
small molecule
Therapeutic area
Oncology · Hematology · Rare Disease
002Signature Detected
FUNDING EVENT
Event type
Research/preclinical milestone (microgravity protein crystallization launch)
Magnitude
Second ADAR1p150 protein crystallization experiment launched to ISS aboard SpaceX CRS-34 (docked May 17, 2026). Aspera's 11th ISS mission overall and second ADAR1p150 flight (first was Crew-12, February 2026). Funded under NASA In Space Production Applications Phase 2.
Lead investor
Aspera Biomedicines (sponsor); experiment payload via Redwire Pharmaceutical In-space Laboratory; launch vehicle SpaceX CRS-34
Participating
Redwire Corporation (PIL hardware), NASA (program funder), SpaceX (launch vehicle)
Use of capital
Non-dilutive: NASA In Space Production Applications Phase 2 award funds the ISS crystallization work. Supports structural resolution of ADAR1p150 toward an oral Rebecsinib formulation.
003Architecture
PLATFORM PROFILE
Target class
ADAR1p150 (adenosine deaminase acting on RNA, p150 isoform; small molecule inhibition for cancer stem cell-driven therapy resistance and immune evasion)
Differentiator
Most ADAR1 work in biotech right now is about recruiting ADAR for therapeutic RNA editing (Korro, AIRNA, Wave). Aspera is going the opposite direction: small molecule inhibition of ADAR1p150 because the enzyme drives cancer stem cell therapy resistance and immune evasion across more than 20 cancers. To get the binding site structurally resolved well enough to design a real oral formulation, the company is running its second microgravity crystallization on the ISS. Eleven flights so far, all building toward an oral version of Rebecsinib.
Lead asset
Rebecsinib (small molecule ADAR1p150 inhibitor, Phase 1/2 in myelofibrosis and secondary AML; FDA IND cleared March 2025)
Pipeline depth
Single disclosed clinical asset: Rebecsinib in Phase 1/2 (myelofibrosis, secondary AML). The current ISS crystallization work is preclinical-stage formulation development supporting an oral version.
004Voyager Assessment
MACHINE-GENERATED
A microgravity launch sounds like a press release flourish. It isn't, in this case. Convection muddies protein crystals on Earth, and ADAR1p150 is a notoriously difficult target to resolve at high resolution. Aspera needs that structure to design an oral Rebecsinib. The clinical Phase 1/2 in myelofibrosis and secondary AML runs in parallel on the IV formulation. If the oral campaign lands, you have an ADAR1 inhibitor a community oncologist could prescribe. Eleven flights is no longer a stunt. It is a strategy.
005Adjacent Structures
FRONTIER MAP
Wave Life Sciences· RNA-editing therapeutics platformKorro Bio· ADAR-recruiting RNA editingAIRNA Therapeutics· site-directed RNA editing for genetic diseaseIncyte· myelofibrosis standard JAK inhibitorAstellas· AML targeted therapy commercialRedwire Corporation· ISS commercial microgravity infrastructureSpaceX· ISS resupply provider
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.